COSMO Pharmaceuticals SA (0RGI) - Total Assets
Based on the latest financial reports, COSMO Pharmaceuticals SA (0RGI) holds total assets worth £695.64 Million GBP (≈ $934.18 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
COSMO Pharmaceuticals SA - Total Assets Trend (2004–2025)
This chart illustrates how COSMO Pharmaceuticals SA's total assets have evolved over time, based on quarterly financial data. Also see market value of COSMO Pharmaceuticals SA for the company's overall valuation and market capitalisation.
COSMO Pharmaceuticals SA - Asset Composition Analysis
Current Asset Composition (December 2025)
COSMO Pharmaceuticals SA's total assets of £695.64 Million consist of 29.9% current assets and 70.1% non-current assets. Review 0RGI liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (GBP) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | £0.00 | 9.1% |
| Accounts Receivable | £25.60 Million | 4.2% |
| Inventory | £10.42 Million | 1.7% |
| Property, Plant & Equipment | £0.00 | 0.0% |
| Intangible Assets | £325.63 Million | 53.2% |
| Goodwill | £23.99 Million | 3.9% |
Asset Composition Trend (2004–2025)
This chart illustrates how COSMO Pharmaceuticals SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See COSMO Pharmaceuticals SA (0RGI) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: COSMO Pharmaceuticals SA's current assets represent 29.9% of total assets in 2025, an increase from 17.7% in 2004.
- Cash Position: Cash and equivalents constituted 9.1% of total assets in 2025, up from 1.2% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 56.0% of total assets, an increase from 4.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 53.2% of total assets.
COSMO Pharmaceuticals SA Competitors by Total Assets
Key competitors of COSMO Pharmaceuticals SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
COSMO Pharmaceuticals SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.66 | 3.84 | 14.68 |
| Quick Ratio | 10.12 | 3.59 | 14.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | £238.62 Million | £138.51 Million | £222.91 Million |
COSMO Pharmaceuticals SA - Advanced Valuation Insights
This section examines the relationship between COSMO Pharmaceuticals SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 1.83 |
| Asset Growth Rate (YoY) | -5.4% |
| Total Assets | £612.16 Million |
| Market Capitalization | $1.12 Billion USD |
Valuation Analysis
Above Book Valuation: The market values COSMO Pharmaceuticals SA's assets above their book value (1.83x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: COSMO Pharmaceuticals SA's assets decreased by 5.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for COSMO Pharmaceuticals SA (2004–2025)
The table below shows the annual total assets of COSMO Pharmaceuticals SA from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | £612.16 Million ≈ $822.07 Million |
-5.35% |
| 2024-12-31 | £646.77 Million ≈ $868.56 Million |
+16.75% |
| 2023-12-31 | £553.98 Million ≈ $743.94 Million |
-27.07% |
| 2022-12-31 | £759.59 Million ≈ $1.02 Billion |
-5.71% |
| 2021-12-31 | £805.56 Million ≈ $1.08 Billion |
+35.12% |
| 2020-12-31 | £596.16 Million ≈ $800.59 Million |
+1.88% |
| 2019-12-31 | £585.16 Million ≈ $785.82 Million |
-6.48% |
| 2018-12-31 | £625.69 Million ≈ $840.24 Million |
+25.65% |
| 2017-12-31 | £497.97 Million ≈ $668.73 Million |
+12.29% |
| 2016-12-31 | £443.47 Million ≈ $595.55 Million |
+1.26% |
| 2015-12-31 | £437.94 Million ≈ $588.12 Million |
+94.11% |
| 2014-12-31 | £225.62 Million ≈ $302.99 Million |
-7.15% |
| 2013-12-31 | £243.00 Million ≈ $326.33 Million |
+32.58% |
| 2012-12-31 | £183.30 Million ≈ $246.15 Million |
+134.88% |
| 2011-12-31 | £78.04 Million ≈ $104.80 Million |
-15.01% |
| 2010-12-31 | £91.83 Million ≈ $123.31 Million |
+28.49% |
| 2009-12-31 | £71.46 Million ≈ $95.97 Million |
+23.72% |
| 2008-12-31 | £57.77 Million ≈ $77.57 Million |
+22.31% |
| 2007-12-31 | £47.23 Million ≈ $63.42 Million |
+100.03% |
| 2006-12-31 | £23.61 Million ≈ $31.71 Million |
-16.31% |
| 2005-12-31 | £28.21 Million ≈ $37.89 Million |
+20.24% |
| 2004-12-31 | £23.46 Million ≈ $31.51 Million |
-- |
About COSMO Pharmaceuticals SA
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant… Read more